文献速递生殖医学产科

代谢综合征对肥胖多囊卵巢综合征患者促排卵结局的影响

Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-20

本研究基于PPCOS II试验数据,分析代谢综合征与肥胖多囊卵巢综合征患者促排卵后活产率及妊娠并发症的关系。结果显示,代谢综合征患者临床妊娠率(20.5% vs 29.7%,P=.007)和活产率(16.5% vs 27%,P=.001)显著降低,妊娠并发症(61.9% vs 44.4%,P=.05)、妊娠期糖尿病(35.7% vs 18.2%,P=.02)和巨大儿(21.4% vs 8.3%,P=.02)发生率更高。

要点

  • 代谢综合征降低肥胖PCOS患者促排卵后的活产率(16.5% vs 27%,P=.001)。
  • 代谢综合征增加妊娠并发症风险,尤其是妊娠期糖尿病和巨大儿。
  • 来曲唑组活产率较高,但代谢综合征时来曲唑产科并发症更多,氯米芬活产率更低。

核心结论

  • 代谢综合征是肥胖PCOS患者促排卵后活产率降低的独立危险因素。
  • 代谢综合征与妊娠并发症风险增加相关,尤其是妊娠期糖尿病和巨大儿。

研究设计与样本

  • 前瞻性队列分析,数据来自PPCOS II临床试验。
  • 750名PCOS不孕女性随机接受氯米芬或来曲唑促排卵1-5周期。
  • 代谢综合征定义为5项心血管代谢危险因素中至少3项。

主要发现

  • 代谢综合征组临床妊娠率20.5% vs 29.7%(P=.007),活产率16.5% vs 27%(P=.001)。
  • 至少1种妊娠并发症发生率61.9% vs 44.4%(P=.05)。
  • 妊娠期糖尿病35.7% vs 18.2%(P=.02),巨大儿21.4% vs 8.3%(P=.02)。
  • BMI 25-35 kg/m2者代谢综合征z评分每增加1单位,活产率比0.89(95%CI 0.79-1.00;P=.04)。
  • 总体妊娠并发症发生率约49%。

关键数值与推荐

  • 代谢综合征定义:腰围>88 cm、HDL-C<50 mg/dL、甘油三酯≥150 mg/dL、收缩压≥130或舒张压≥85 mm Hg、空腹血糖>100 mg/dL中至少3项。
  • BMI分类:正常<25 kg/m2,高25-35 kg/m2,极高>35 kg/m2。

临床怎么用

  • 对肥胖PCOS患者促排卵前应评估代谢综合征,以预测活产率和妊娠并发症风险。
  • 合并代谢综合征者需加强妊娠期糖尿病和巨大儿的监测。
  • 药物选择需考虑代谢综合征状态:氯米芬活产率较低,来曲唑产科并发症较多。

局限性

  • 极高BMI亚组中代谢综合征与肥胖的独立效应难以区分。
  • 研究为二次分析,代谢综合征对特定药物结局的影响需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is common in women with polycystic ovary syndrome. polycystic ovary syndrome and obesity are associated with reduced fertility. The effect of metabolic syndrome on the success of infertility treatment and pregnancy outcomes in women with polycystic ovary syndrome undergoing ovulation induction has not been investigated. OBJECTIVE: The objectives of this study were to determine the associations of metabolic syndrome on the rate of live birth after ovulation induction and pregnancy complications in obese women with polycystic ovary syndrome and determine whether there is a difference in outcomes concerning specific medications used for ovulation induction. STUDY DESIGN: This prospective cohort analysis used data collected from participants in the Pregnancy in Polycystic Ovary Syndrome II clinical trial conducted by the Reproductive Medicine Network. In the Pregnancy in Polycystic Ovary Syndrome II trial, 750 women with polycystic ovary syndrome and infertility were randomized to either clomiphene citrate or letrozole for ovulation induction for 1 to 5 cycles or until pregnancy occurred. Cox regression and modified Poisson regression, chi-square test, and Student t test or Wilcoxon test were used in this study. Outcomes of interest were rates of live birth and clinical pregnancy and pregnancy complications. Having metabolic syndrome was defined by the presence of at least 3 of 5 cardiometabolic risk factors (waist circumference of >88 cm, low high-density lipoprotein cholesterol of <50 mg/dL, triglycerides of ≥150 mg/dL, systolic blood pressure of ≥130 or diastolic blood pressure of ≥85 mm Hg, and fasting glucose of >100 mg/dL). In addition, we used a continuous metabolic syndrome z score. Body mass index categories were defined as normal (body mass index of <25 kg/m2), high (25 to 35 kg/m2), and very high (>35 kg/m2). RESULTS: As illustrated in the Table, early pregnancy losses showed no difference by metabolic syndrome. Fewer women achieved a clinical pregnancy (20.5% vs 29.7%; P=.007) or had a live birth (16.5% vs 27%; P=.001) in the presence of metabolic syndrome. Early pregnancy losses showed no difference by metabolic syndrome status. However, at least 1 pregnancy complication occurred more often with metabolic syndrome: 61.9% (26 of 42 cases) with metabolic syndrome vs 44.4% (59 of 133 cases) (P=.05) without metabolic syndrome. Gestational diabetes mellitus (35.7% vs 18.2%; P=.02) and macrosomia (21.4% vs 8.3%; P=.02) were more common in the presence of metabolic syndrome. After adjustment for other potential confounders, the rate ratio for live births for a 1-unit change in the metabolic syndrome z score was 0.89 (95% confidence interval, 0.79-1.00; P=.04) for those whose body mass index was 25 to 35 kg/m2. For the very high body mass index subgroup (>35 kg/m2), the independent effects of metabolic syndrome from obesity were harder to discern. The rate of live birth was higher with the use of letrozole, although metabolic syndrome had a different detrimental effect concerning the medication given. The overall incidence of pregnancy complications was high (approximately 49%) in the Pregnancy in Polycystic Ovary Syndrome II trial and the 2 medications. Letrozole was associated with more obstetrical complications in the presence of metabolic syndrome, and clomiphene was associated with a lower rate of live birth rate when metabolic syndrome was present. CONCLUSION: Metabolic syndrome is a risk factor that lowers the rate of live birth after ovulation for women with polycystic ovary syndrome, independent of obesity, and it is particularly associated with a lower rate of live birth for women using clomiphene compared with women using letrozole. In addition, metabolic syndrome is a risk factor for pregnancy complications for women with obesity using letrozole. Furthermore, having metabolic syndrome is a risk factor for gestational diabetes mellitus and macrosomia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Arya S, Hansen KR, Peck JD, et al. Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome. Am J Obstet Gynecol. 2021. PMID: 33852887. doi:10.1016/j.ajog.2021.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。